抗生素概论 Review of Antibiotics Part 1课件.ppt

* * * * * Purpose of slide: To provide an overview of important facts about daptomycin. Refer to the notes associated with the individual slides that follow this overview. Reference CUBICIN? Prescribing Information, 2005. * Mandatory slide Daptomycin is indicated for the treatment of complicated skin and skin-structure infections caused by susceptible strains of the following Gram-positive microorganisms: Staphylococcus aureus (including 267 methicillin-resistant strains) Streptococcus pyogenes Streptococcus agalactiae Streptococcus dysgalactiae subsp equisimilis Enterococcus faecalis (vancomycin-susceptible strains only) Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram-negative or anaerobic organisms. Daptomycin is not indicated for the treatment of pneumonia: results of phase 3 studies of community-acquired pneumonia (CAP) found daptomycin to be less effective than ceftriaxone for community acquired pneumonia. The death rate and rates of serious cardiorespiratory adverse events were higher in daptomycin-treated patients than in comparator-treated patients. These differences were due to lack of therapeutic effectiveness of daptomycin in the treatment of CAP in patients experiencing these adverse events. Subsequent research has demonstrated that daptomycin is inhibited by physiological concentrations of pulmonary surfactant. Thus daptomycin should not be used to treat pulmonary infections. References CUBICIN? Prescribing Information, 2005. Silverman JA, Mortin LI, VanPraagh ADG, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191:2149-2152. * In vitro, daptomycin exhibits potency against organisms resistant to methicillin, vancomycin, and linezolid. Daptomycin has in vitro activity against a broad range of anaerobic Gram-positive microorganisms: Peptostreptococcus spp Clostridium perfringens Clostridium difficile And other vancomycin-resistant